Sangamo BioSciences Logo
Sangamo BioSciences
  • About Us
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Business Development
    • Sangamo in the News
    • Contact Us
  • Product Pipeline
    • SB-728
    • SB-313
    • Hemophilia
    • Huntington’s disease
    • Rare Diseases
    • Clinical Trials
    • Publications
  • Technology Platform
    • ZFP Transcription Factors
    • ZFP Nucleases
    • Therapeutic Applications
    • Non-Therapeutic Applications
    • Publications
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Investor FAQs
    • Contact Us
  • Careers
    • Job Opportunities
    • Benefits

ZFN technology for HIV/AIDS

Sangamo has a Phase 2 and two Phase 1/2 clinical trials to evaluate our ZFP Therapeutic® SB-728-T in T-cells for the treatment of HIV/AIDS Read More

2012 Form 10K

Our 2012 10K is now available for download. Download Now

Latest News

5/24/2013
Sangamo BioSciences Receives $6.4 Million Strategic Partnership Award From California Institute for Regenerative Medicine (CIRM) to Develop ZFP Therapeutic® for Beta-thalassemia

5/20/2013
Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics® For Monogenic Diseases

More News

Product Pipeline

View Complete Pipeline

© sangamo.com     Website design: Hane Chow Inc.
  • Terms Of Use
  • Privacy
  • Legal Notice